Right Brain Bio Selected for Dassault Systèmes' 3DEXPERIENCE Lab; Accelerating Phase 2 Development of Novel Parkinson's Therapy
Selection Provides Access to Dassault Systèmes' Industry-Leading MEDIDATA Clinical Trial Platform as Right Brain Bio Prepares for Phase 2 Study of RB-190 for Parkinson's Disease PLEASANTVILLE, N.Y., June 22, 2026 /PRNewswire/ -- Right Brain Bio, Inc. (RBB), a clinical-stage biotechnology...
Selection Provides Access to Dassault Systèmes' Industry-Leading MEDIDATA Clinical Trial Platform as Right Brain Bio Prepares for Phase 2 Study of RB-190 for Parkinson's Disease PLEASANTVILLE, N.Y., June 22, 2026 /PRNewswire/ -- Right Brain Bio, Inc. (RBB), a clinical-stage biotechnology...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.